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Once considered solely medical waste and routinely
discarded as part of the afterbirth, umbilical cord blood (CB)
is now commonly used as a source of hematopoietic stem
cells (HSCs) for patients in need of HSC transplantation
(HSCT) (or, as more commonly referred to, bone marrow
transplantation) for the treatment of both malignant and
nonmalignant disorders. In fact, more than 20,000 CB
transplantations (CBTs) have been performed since the ﬁrst
one in 1988 [1], and this number increases annually as more
recent data demonstrate outcomes for CBT recipients paral-
leling those for conventional HSCT recipients.
Numerous factors make CB a desirable source of HSCs,
including ease of procurement and lack of donor attrition,
with the ability to process and store the donor cells long
term [2]. Importantly, CB donors can be used without the
need for a “perfect” HLA match, thereby increasing donor
access to HSCT, particularly for minority and mixed ethnicity
patients, for whom a suitably matched related or unrelated
donor may be difﬁcult to locate. Moreover, despite the
greater degree of HLA mismatch, CBT recipients are at
decreased risk of developing chronic graft-versus-host
disease (GVHD).
The ﬁrst decade of CBT experience was important in
deﬁning critical total nucleated cell (TNC) and CD34þ cell
dose thresholds required for acceptable clinical outcomes,
and in moving from related to unrelated donor CBT and from
pediatric to adult patients. The limitations of this approach
also were deﬁned during this period, with low cell dose
identiﬁed as the critical barrier. CBT recipients receive
on average only 10% of the CD34þ stem/progenitor cells
provided in conventional bone marrow grafts and only 5% of
those provided in peripheral blood stem cell grafts, resulting
in signiﬁcant delays in engraftment and immune reconsti-
tution, as well as an increased risk of graft failure and early
transplantation-related mortality.
Despite these limitations, the second decade of CBT was
marked by improved outcomes, especially in adults, as better
knowledge of cell dose requirements led to improved
collection and the availability of units with higher cell doses.
Better supportive care also contributed to these improved
outcomes. Initial reports showed outcomes for CBT recipi-
ents on par with conventional HSCT recipients [3-5]. Finally,Financial disclosure: See Acknowledgments on page S77.
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reduction in the risk of graft failure, opening up the possi-
bility of HSCT with CB for essentially all patients without
a suitable donor [6]. Nonetheless, the use of dCBT did not
produce faster neutrophil recovery or immune reconstitu-
tion, with cell dose remaining a major limitation. The advent
of dCBT has, however, led to increased activity in the area of
CB graft engineering, especially in the area of ex vivo
expansion, with the double-unit platform allowing for
manipulation of 1 unit and the ability to track both units
in vivo.
Ex vivo expansion of CB stem and progenitor cells to
enhance engraftment is only one area of CB graft engineering
currently under clinical investigation. As discussed below in
more detail, the generation of immunotherapy fromCB grafts
is under active investigation both preclinically and now in
the clinic as a means of overcoming the issues of delayed
immune reconstitution in CBT recipients, with the genera-
tion of multivirus-speciﬁc cytotoxic T lymphocytes to treat
viral infections. Relapse also remains a problem for all
patients undergoing HSCT for hematologic malignancy. The
ex vivo expansion of CB-derived T cells genetically modiﬁed
to express CD19 or CD20 chimeric antigen receptors (CARs)
to prevent relapse and the ex vivo generation of increased
numbers of CB-derived NK cells as a means of better dis-
ease control are discussed below. This review focuses on
these primary areas of graft engineering, but by no means
represents an exhaustive list of the active research ongoing
in the ﬁeld of CB graft engineering. Other areas not covered
in this review include the generation of regulatory T cells
for GVHD prophylaxis, biological-based bioengineering
approaches to enhance stem cell expansion, and preclinical
research into the generation of CB-derived induced plurip-
otent stem cells. With continued advancement in the ﬁeld, it
is possible that a single CB unit could be manipulated based
on an individual patient’s greatest clinical need, with
generation of speciﬁc cell types as clinically appropriate
(Figure 1).CB STEM/PROGENITOR CELL EXPANSION TO ENHANCE
ENGRAFTMENT
Multiple strategies currently under clinical investigation
are aimed at overcoming the greatest hurdle in the use of CB
grafts, namely the low total cell and stem cell doses provided
by a single or double CB graft, which results in signiﬁcant
delays in hematopoietic recovery and increased risk of
primary graft failure, especially in adult patients. These
strategies focus primarily, but not exclusively, on methods to
increase the cell dose of CB grafts and includeTransplantation.
Figure 1. The potential of CB graft engineering.
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expanded CB units [7,8], direct intrabone marrow injection
[9], coinfusion of a CB unit with a haploidentical T cellede-
pleted graft [10,11], systemic addition of mesenchymal stem
cells (MSCs) [12], and the use of agents to enhance the
homing of CB to the marrow [13].
Double CBT (dCBT) is now commonly used in the adult
setting to achieve an adequate cell dose and has dramatically
increased access to HCT for adult and larger pediatric
patients who do not have an adequately sized single CB
unit available. However, the median time to neutrophil
recovery has not been signiﬁcantly impacted despite
a doubling of the cell dose with this approach, with
a median time to neutrophil recovery of 26 days after
a myeloablative preparative regimen [14]. Furthermore,
nonrelapse mortality (NRM) was higher in dCBT recipients
compared with recipients of grafts from matched and mis-
matched unrelated donors, with the majority of the NRM
occurring within the ﬁrst 100 days posttransplantation.
Importantly, an analysis of the risk factors for NRM among
dCBT recipients revealed an elevated risk in patients
with delayed myeloid recovery (time to absolute neutrophil
count >500/mL) if the recovery took 26 days or longer (the
median time to engraftment in dCBT recipients). Thus, the
signiﬁcant delay in neutrophil recovery observed in CBT
recipients remains a critical barrier to successful outcomes
in the CBT setting and may be overcome by clinically
feasible ex vivo expansion of CB hematopoietic stem and
progenitor cells.
CB Stem/Progenitor Cell Expansion to Enhance
Engraftment
Ex vivo expansion of CB-derived hematopoietic stem and
progenitor cells before infusion is currently under study as
a way to shorten the time to neutrophil engraftment and
reduce the rate of graft failure. Extremely promising results
have been reported by Delaney et al. [15] using an engi-
neered form of the Notch ligand Delta1 for the ex vivo
generation of increased numbers of CB CD34þ stem and
progenitor cells, with the goal of reducing the time to
engraftment. Preliminary results, published in 2010,
demonstrated both the safety and clinical feasibility of this
approach, as well as a signiﬁcant decrease in the time to
neutrophil recovery. Updated data (unpublished) from thisongoing study, nowwith 17 patients, shows amedian time to
neutrophil recovery (absolute neutrophil count 500/mL) of
11 days, compared with 25 days in a concurrent institutional
cohort of patients (n ¼ 36) treated with the same condi-
tioning regimen and dCBT. Of note, the expanded cell grafts
used in this study contributed almost exclusively to the
initial myeloid engraftment observed at 1 week, demon-
strating an enhanced capacity of the expanded cells to
provide rapid myeloid recovery. Furthermore, all but 2
evaluable subjects engrafted before day 21, independent of
whether the expanded cell graft persisted in vivo. Of note,
the unit that was expanded ex vivo underwent positive
selection for CD34þ cells to initiate in culture, and the
negative fraction from this unit was not infused at the time of
transplantation.
Robinson et al. [16] reported a 10- to 20-fold increase in
total nucleated cells and a 16- to 40-fold increase in CD34þ
cells using a strategy to culture CB cells with MSCs. Based on
those results, a clinical trial was initiated to evaluate
the ex vivo coculture of CB mononuclear cells with either
third-party haploidentical family member marrow-derived
MSCs or off-the-shelf Stro3þ MSCs from Mesoblast (Meso-
blast Limited, Melbourne, Australia) (ClinicalTrials.gov; NCT
00498316), again with quite promising results. The results
were similar with either source of MSCs, with prompt
engraftment of neutrophils in 15 days and of platelets in 42
days [17]. Long-term engraftment was provided by the
unexpanded unit in the majority of patients. These results
provide the rationale for a planned prospectivemultinational
randomized trial comparing unmanipulated dCBT with dCBT
in which 1 of the units is expanded in MSC cocultures.
Unlike the previous 2 studies that used a dBCT platform in
which 1 CB unit is manipulated and the other is ex vivo
expanded, a trial in which a fraction of a single CB unit was
ex vivo expanded using growth factors in conjunction of the
copper chelator tetraethylpentamine [18] was sponsored by
Gamida Cell (Gamida Cell Ltd. - Stem Cell Therapy Technol-
ogies, Jerusalem, Israel). Preliminary analysis revealed faster
engraftment and improved survival compared with histor-
ical control recipients of single CBT reported to international
registries [8], and amore deﬁnitive analysis of these data is in
progress. In other preclinical studies by this group, CB-
derived CD34þ cells cultured ex vivo with growth factors
(stem cell factor, thrombopoietin, IL-6, and FLT3) and nico-
tinamide displayed increased migration toward stromal
cellederived factor 1 and enhanced homing to bone marrow
compared with untreated CB [19]. A multicenter pilot clinical
trial is in progress to evaluate this strategy in the myeloa-
blative dCBT setting (ClinicalTrials.gov; NCT01221857).
Preliminary analysis has shown rapid engraftment (10 days
for neutrophils and 30 days for platelets), with, interestingly,
sustained engraftment coming from the expanded unit in the
majority of patients evaluated to date (M.E. Horowitz,
personal communication).
Improving CB Homing to Bone Marrow
An alternative strategy for overcoming delayed hemato-
poietic recovery is correction of the decreased fucosylation of
CB cell surface molecules, which is thought to impair homing
of the limited numbers of stem and progenitor cells in the CB
graft to the bone marrow [20]. Preclinical murine xenograft
models of Robinson et al. [13] demonstrated that human CB-
derived CD34þ cells treated with fucosyltransferase-VI
before infusion resulted in more rapid and higher levels of
human engraftment compared with untreated CB units. A
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receive a dCBT with 1 CB unit fucosylated before infusion
(ClinicalTrials.gov; NCT 01471067). In future trials,
combining CB expansion with fucosylation may produce
maximally rapid hematopoietic recovery.
Additional approaches have been investigated with the
goal of improving homing of CB stem/progenitor cells. North
et al. [21] used a high-throughput screen to identify potential
regulators of HSC fate and cell renewal, identifying prosta-
glandin E2 (PGE2) as capable of enhancing HSC formation in
zebraﬁsh. Additional studies have shown that PGE2 may
enhance HSC homing, survival, and proliferation [22]. Based
on these data, Cutler et al. [23] are currently conducting
a clinical trial to evaluate the ex vivo treatment of 1 of 2 CB
units with dimethyl PGE2 before infusion (ClinicalTrials.gov;
NCT 00890500). Once the procedure was optimized,
neutrophil engraftment was prompt (17 days), with domi-
nance of the dimethyl PGE2emodulated unit documented in
the majority of recipients [23].
Inhibition of the CD34þ CB cell surface protein CD26/
dipeptidylpeptidase (DPPIV) has been shown by Broxmeyer
et al. [24,25] to enhance engraftment in sublethally irradi-
ated NOD/SCID mice. Similar to the PGE2 study, the investi-
gators are currently conducting a clinical trial of systemic
sitagliptin, a US Food and Drug Administratione approved
DPPIV inhibitor for diabetes, to evaluate the potential
for enhancing engraftment in recipients of a single CBT
(ClinicalTrials.gov; NCT 00862719).
ENGINEERING IMMUNOTHERAPY FROM CB GRAFTS
Expanding Multivirus-Speciﬁc Cytotoxic T Lymphocytes
from CB
CBT is associated with signiﬁcant morbidity andmortality
from viral infections, including cytomegalovirus (CMV),
Epstein-Barr virus (EBV), and adenovirus (Ad). This suscep-
tibility to viral complications is related to the antigen-
inexperienced nature of CB, which contains a high
percentage of naïve T cells compared with peripheral blood
(PB). Virus-speciﬁc memory T cells are critical in noneT
celledepleted grafts, conferring protection against viral
infections and reactivation and even relapse. Inadequacies in
current pharmacologic antiviral agents have increased the
interest in an immunotherapeutic approach to viral disor-
ders. Adoptive transfer of T cells by donor lymphocyte infu-
sion has been used to treat viral infection after allogeneic
HSCT, but this carries a risk of GVHD. In contrast, PB-derived
virus-speciﬁc cytotoxic T lymphocytes (CTLs) directed to
CMV, EBV, and Ad can rapidly reconstitute antiviral immu-
nity post-HSCT without GVHD [26-29]. Thus, we sought to
evaluate whether this strategy could similarly be applied to
recipients of CBT recipients. However, certain obstacles had
to be circumvented ﬁrst, including the naivety of the
CB-derived T cells and the limited cell numbers available for
manipulation in the CB graft [30].
Because of these challenges, only a few investigators have
attempted to generate CMV and EBV antigen-speciﬁc T cells
from CB in proof-of-principle studies [31,32]. Neither
approach has been used clinically, however. Consequently,
we set out to develop a good manufacturing practi-
cesecompliant methodology for direct translation.
Ad5f35pp65-transduced CB-derived antigen-presenting
cells (dendritic cells and EBV-transformed lymphoblastoid
cell lines) can be used to generate large numbers of
CB-derived T cells speciﬁc for CMV, Ad, and EBV. We antici-
pated that our ability to generate for adoptive transfer virus-speciﬁc CTLs from CB recognizing a broad spectrum of
epitopes recognized by both CD4þ and CD8þ T cells
would minimize the risk of viral escape and maximize the
therapeutic beneﬁt to CB recipients at risk for severe viral
disease [30].
We have opened a clinical trial using CB-derived multi-
virus-speciﬁc Tcells for the prevention and treatment of viral
infection after CBT (ClinicalTrials.gov; NCT 01017705). To
date, 10 patients have received single CBT using the 80%
fraction of a fractionated CB unit. All patients engrafted
neutrophils and platelets at <30 days and 60 days post-
CBT, respectively. Multivirus-speciﬁc CTLs were generated
from the remaining 20% fraction of the CB graft and have
been infused in 7 patients. Patients received the CTLs at
a median of 83 days after CBT (range, 63-146 days). None of
the patients has demonstrated infusion-related toxicity or
GVHD.
Only 2 patients have developed a viral infection, and all
patients have remained free of CMV, EBV, and Ad infection/
reactivation from 2 months to 2 years after CBT. One patient
developed CMV reactivation early post-CBT and cleared the
virus after 2 CTL infusions. This patient was also positive for
Ad antigen in his stool, which resolved without additional
therapy, and he remains asymptomatic and virus-free more
than 2 years after CBT. Another patient had detectable EBV
DNA in the PB that was controlled without antiviral therapy.
To determine the persistence of the CB CTLs, we used deep
T cell receptor sequencing by Adaptive Biotechnologies
(Seattle, Washington). T cell clones present in the infused
CTLs but not present before CTL infusionwere detected up to
1 year after CBT in all patients tested. Thus, administration of
CB-derived virus-speciﬁc CTLs to patients after CBT has so far
been safe, and can facilitate reconstitution of virus-speciﬁc T
cells and control viral reactivation/infection in vivo.
Redirecting Speciﬁcity of CB-Derived T Cells to Leukemia
Antigens
Although the control of viral infections by infusion of CB-
derived multivirus-speciﬁc CTLs would represent a signiﬁ-
cant improvement in the outcome of CBT, disease relapse
remains a problem. Targeting malignancies using exogenous
receptors (chimeric antigen receptors [CARs]) expressed on
PB ex vivo expanded T cells is an evolving therapy for both
hematologic malignancies and solid tumors [33]. In recent
years, this approach has been translated to the CB setting by
expanding CB-derived T cells that are genetically modiﬁed to
express CD19 or CD20 CARs [34]. A major advantage of CARs
is their MHC-independent antigen recognition of native
molecules rather than processed proteins. B cellederived
malignancies are particularlywell suited to targeting by CAR-
expressing T cells, given that tumor cells almost invariably
express CD19, an antigen restricted to B lymphocytes and not
present on HSCs. As has been demonstrated in several clin-
ical trials, T lymphocytes expressing a transgenic CAR
directed to CD19 are highly effective in eliminating CD19þ
tumors [35,36]. To develop a “bispeciﬁc” T cell strategy tar-
geting both tumor and viral antigens for patients after CBT,
Micklethwaite et al. [37] transduced multivirus-speciﬁc
T cells derived from PB and CB with a CD19 CAR and
showed that these gene-modiﬁed T cells exhibit both anti-
viral and antitumor activity in vitro.
In a proof-of-principle study, we evaluated whether this
approach is safe in recipients of PB stem cell transplants. Six
patients (2 with relapsed acute lymphoblastic leukemia, 2
with chronic lymphocytic leukemia [CLL], and 2 with CLL/
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multivirus-speciﬁc T cells, with no infusion-related toxicity.
Transduced T cells were detected in the PB and in disease
sites, including the gastrointestinal tract, bone marrow, and
lymph nodes, for up to 9 weeks postinfusion. Antitumor
effects were seen in 4 patients, including 1 patient with
Philadelphia chromosomeepositive acute lymphoblastic
leukemia who had 4% blasts detectable in the PB, which
cleared within 2 weeks of T cell infusion. One patient
with adenovirus in the stool resolved without antiviral
treatment. No other patient developed viral infections
posttransplantation. These early results provide encouraging
evidence of the safety and effectiveness ofmonoculture CD19
CAR trivirus T cells for patients after allogeneic HSCT and also
has the potential to afford CBT recipients sustained protec-
tion against both malignant relapse and lethal viral
infections.CB-Derived Natural Killer Cells
Natural killer (NK) cells are innate immune cells that
recognize “nonself" by the absence of class I molecules and
inhibitory receptors. Although the proportion of NK cells in
CB is similar to that in adult PB, the NK cells in CB are
immature in both phenotype and function. Given the
promise of allogeneic NK cell therapy, several groups have
developed methods to isolate NK cells from PB of healthy
donors [38]. However, CB-derived products are seriously
restricted by the ﬁnite number of cells available for expan-
sion. This limitation has led to new methods for expanding
NK cells in vitro. To optimize the system, we explored the use
of cytokines, artiﬁcial antigen-presenting cells, and the
G-REX gas-permeable device. After expansion, CB NK cells
demonstrated cytolytic function in vitro against multiple
hematologic tumor targets. Furthermore, when expanded CB
NK cells were transferred to murine models of human acute
myelogenous leukemia and CLL, the NK cells exhibited
in vivo antileukemic activity, supporting the use of donor-
derived CB NK cells to prevent relapse [39]. Whether
ex vivo expanded CB NK cells will be more efﬁcacious in this
setting remains to be tested, however.
In summary, despite the many advantages of CB as
a source of allogeneic HSCs, the use of CB immune cells for
clinical use is still in its infancy. Although the infusion of CB-
derived multivirus-speciﬁc T cells shows promise in the
single CBT setting, it has yet to be applied in the dCBT setting.
Furthermore, the use of CB-derived leukemia-speciﬁc T cells
and NK cells remains to be translated to the clinical setting to
enable researchers to evaluate and optimize the successes
and failures of these approaches. Nevertheless, CB-derived
immune-based therapies ultimately have the potential to
greatly improve the outcomes for these patients.ACKNOWLEDGMENTS
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